Covid-19
Bad news for Paxlovid? Coronavirus can find multiple ways to evade COVID-19 drug.
4 Jul, 2022 | 12:57h | UTCBad news for Paxlovid? Coronavirus can find multiple ways to evade COVID-19 drug – Science
See also: SARS-CoV-2 can evade Paxlovid by multiple mechanisms – News Medical
Opinion | FDA: Don’t rush a move to change the Covid-19 vaccine composition.
4 Jul, 2022 | 12:53h | UTCFDA: Don’t rush a move to change the Covid-19 vaccine composition – STAT
Antibodies to combat viral infections: development strategies and progress.
4 Jul, 2022 | 12:51h | UTCAntibodies to combat viral infections: development strategies and progress – Nature Reviews Drug Discovery (if the link is paywalled, try this one in PMC)
2022 Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
1 Jul, 2022 | 11:50h | UTCRelated:
Two new studies show no benefit of Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19.
1 Jul, 2022 | 11:49h | UTCCommentaries:
Antithrombotic Prophylaxis No Help in Outpatients With COVID — Two trials show no differences between patients who received enoxaparin vs standard of care – MedPage Today (free registration required)
Commentary on Twitter (thread – click for more)
Early in the pandemic we wondered whether antithrombotic therapy in outpatients with #COVID19 would prevent #thrombosis ❓
Several trials were started globally and the ACTIV-4B trial was previously reported⬇️ https://t.co/Q15WcZwDIA
Now, we publish the OVID and ETHIC trials🧵
— The Lancet Haematology (@TheLancetHaem) June 30, 2022
Accuracy of rapid antigen vs. RT-PCR testing for SARS-CoV-2 infection in college athletes during prevalence of the Omicron variant.
1 Jul, 2022 | 11:39h | UTC
Commentary on Twitter
In this case series of college athletes returning to campus during Omicron, rapid antigen tests were 63% sensitive, >99% specific for #COVID19, similar to previous strains and less well in detecting asymptomatic #SARSCoV2. @helixcardinal @stanford_ortho https://t.co/SBPr6NQ9Na
— JAMA Network Open (@JAMANetworkOpen) June 15, 2022
Cohort Study: Effectiveness of Pfizer, Moderna, and AstraZeneca vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting.
1 Jul, 2022 | 11:37h | UTC
Commentary on Twitter
🎉 Read our latest research article comparing the effectiveness of three #COVID vaccines against severe COVID outcomes. ▶️ https://t.co/uaQNgnDrrV#BMJMedicine #MedTwitter #openaccess pic.twitter.com/4oeG5d0j80
— BMJMedicine (@BMJMedicine) June 16, 2022
Cohort Study: Pfizer vaccine effectiveness against omicron in children 5 to 11 years of age.
30 Jun, 2022 | 11:21h | UTC
Wearable activity trackers plus AI might be used to pick up presymptomatic COVID-19.
30 Jun, 2022 | 11:18h | UTCNews Release: Wearable activity trackers + AI might be used to pick up presymptomatic COVID-19 – BMJ Newsroom
Systematic Review: Long distance airborne transmission of SARS-CoV-2.
30 Jun, 2022 | 11:17h | UTCLong distance airborne transmission of SARS-CoV-2: rapid systematic review – The BMJ
Editorial: Airborne SARS-CoV-2 – The BMJ
News Release: New review of evidence highlights importance of adequate ventilation to prevent spread of covid-19 in indoor settings – BMJ
RCT: A 2-week interruption in methotrexate treatment doubles the antibody response to a COVID-19 booster vaccine.
29 Jun, 2022 | 12:10h | UTCNews Releases:
Interrupting immune-suppressing treatment can boost COVID vaccine response – Imperial College London
Commentaries:
Commentary on Twitter
NEW Research—2-week interruption of methotrexate treatment for people w/ immune-mediated inflammatory diseases = enhanced boosting of antibody responses after #COVID19 vaccination
From Prof Abhishek Abhishek & colleagues https://t.co/y14pUEaB5X pic.twitter.com/pLvaXjJzoz
— The Lancet Respiratory Medicine (@LancetRespirMed) June 28, 2022
Perspective | Fast-evolving COVID variants complicate vaccine updates.
29 Jun, 2022 | 12:01h | UTCFast-evolving COVID variants complicate vaccine updates – Nature
Retrospective Cohort Study: Key characteristics impacting survival of COVID-19 extracorporeal membrane oxygenation.
29 Jun, 2022 | 11:54h | UTC
An analysis of SARS-CoV-2 vaccine reactogenicity: variation by type, dose, and history, severity, and recency of prior SARS-CoV-2 infection.
29 Jun, 2022 | 11:52h | UTC
Long COVID symptoms in SARS-CoV-2-positive children aged 0–14 years and matched controls in Denmark: a national, cross-sectional study.
28 Jun, 2022 | 11:16h | UTCNews Release: Largest study reports long COVID symptoms in children up to age 14 – Lancet
Commentaries:
Difficult questions about long COVID in children – The Lancet Child & Adolescent Health
Kids do get long COVID, but it seems uncommon, data reveal – CIDRAP
Cardiovascular damage in COVID-19: What we know two years later.
28 Jun, 2022 | 11:11h | UTCCardiovascular Damage in COVID-19: What We Know Two Years Later – Current Cardiology Reports
Cohort Study: Association of receipt of the fourth BNT162b2 dose with omicron infection and COVID-19 hospitalizations among residents of long-term care facilities.
28 Jun, 2022 | 11:08h | UTCCommentary: Fourth Dose of BNT162b2 Prevents Severe COVID-19 in Nursing Home Residents – HealthDay
Commentary on Twitter
Cohort study found that vaccination with a fourth BNT162b2 dose vs 3 doses given 4 months or earlier, was associated with lower risk of hospitalizations by 64-67% and deaths by 72%, among residents of long-term care facilities during massive Omicron surge. https://t.co/LTZ4umgSDh
— JAMA Internal Medicine (@JAMAInternalMed) June 23, 2022
2022 AHA/ACC key data elements and definitions for cardiovascular and noncardiovascular complications of COVID-19.
27 Jun, 2022 | 12:01h | UTCNews Release: New ACC/AHA Data Standards Address CV, Noncardiovascular Complications of COVID-19 – American College of Cardiology
Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada.
27 Jun, 2022 | 11:51h | UTCCommentary: Young Men’s Myocarditis Risk 5 Times Higher With Moderna vs Pfizer Vax — But Canadian study finds that 8-week interval before second dose attenuates some of the risk – MedPage Today (free registration required)
[Press Release – not published yet]: RCT: Sanofi-GSK report its vaccine targeted against ancestral and Beta strains had an overall efficacy of 72% against the Omicron variant.
27 Jun, 2022 | 11:52h | UTCPress Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine – Sanofi
Commentaries: Bivalent COVID Vax Gets Phase III Win Against Omicron, Companies Say — Sanofi, GSK boast of 72% efficacy against Omicron variant – MedPage Today (free registration required)
Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19.
27 Jun, 2022 | 11:49h | UTC
Commentary on Twitter
NEW Personal View—Use of pragmatic and explanatory trial designs in acute care research: lessons from #COVID19
From Jonathan Casey & colleagues https://t.co/3vJs5j6Q1Q pic.twitter.com/hEUFYxNKRf
— The Lancet Respiratory Medicine (@LancetRespirMed) June 14, 2022
Perspective | What Omicron’s BA.4 and BA.5 variants mean for the pandemic.
27 Jun, 2022 | 11:48h | UTCWhat Omicron’s BA.4 and BA.5 variants mean for the pandemic – Nature
Vaccinations may have prevented almost 20 million COVID-19 deaths worldwide.
27 Jun, 2022 | 11:46h | UTCNews Release: Vaccinations may have prevented almost 20 million COVID-19 deaths worldwide – Imperial College London
Original Study: Global impact of the first year of COVID-19 vaccination: a mathematical modelling study – The Lancet Infectious Diseases
Commentaries:
Covid-19 vaccines prevented nearly 20 million deaths in a year, study estimates – STAT
COVID-19 vaccines saved an estimated 20 million lives in 1 year – CIDRAP
Commentary on Twitter (thread – click for more)
🆕 @TheLancetInfDis
In the 1st year of Covid vaccinations, ~20 million deaths were prevented worldwide (data from 185 countries)
Another ~600,000 lives would have been saved if the @WHO 40% target been achievedhttps://t.co/BWig83xlnN @azraghani @imperialcollege @MRC_Outbreak pic.twitter.com/lF8biBJIlK— Eric Topol (@EricTopol) June 23, 2022
New COVID drugs face delays as trials grow more difficult.
24 Jun, 2022 | 11:47h | UTCNew COVID drugs face delays as trials grow more difficult – Nature
Perspective | Four areas of health innovation boosted by the pandemic.
24 Jun, 2022 | 11:36h | UTCFour areas of health innovation boosted by the pandemic – Nature Medicine
Commentary on Twitter
Leading researchers speak with @NatureMedicine about how the COVID-19 pandemic has spurred research on wearables, genomic surveillance, behavioral interventions and drug discovery. https://t.co/k3Svb0xBVB
— Nature Portfolio (@NaturePortfolio) June 17, 2022